Aegis Financial Corporation and Scott L. Barbee filed Amendment No. 2 to a Schedule 13G with the SEC on November 13, 2026, disclosing a combined beneficial ownership position in Natural Gas Services Group, Inc. common stock as of September 30, 2026.
Three affiliated investment advisers filed a Schedule 13G on November 13, 2026, disclosing aggregate beneficial ownership positions in the Class A ordinary shares of Plutonian Acquisition Corp. II (NYSE:PLUN) as of September 30, 2026.
Westchester Capital Management, LLC and Westchester Capital Partners, LLC filed an amended Schedule 13G with the SEC on November 13, 2026, disclosing their combined beneficial ownership of Class A ordinary shares in GigCapital8 Corp as of September 30, 2026.
Westchester Capital Management, LLC, Westchester Capital Partners, LLC, and Virtus Investment Advisers, LLC filed a joint Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership positions in Disciplined Growth Acquisition Corporation as of September 30, 2026.
Cohen & Steers, Inc. filed a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 15,432,792 shares of CubeSmart common stock as of September 30, 2026, representing 6.85% of the class.
Cohen & Steers, Inc. filed Amendment No. 12 to Schedule 13G with the SEC on November 13, 2026, reporting beneficial ownership of common stock in Invitation Homes, Inc. as of September 30, 2026.
Cohen & Steers, Inc. filed Amendment No. 2 to its Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 15,736,987 shares of Kite Realty Group Trust common stock as of September 30, 2026.
Cohen & Steers, Inc. filed Amendment No. 3 to Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 49,435,541 shares of Healthcare Realty Trust Inc common stock as of September 30, 2026.
SmartKem, Inc. filed a Form S-4 registration statement and preliminary proxy statement/prospectus with the U.S. Securities and Exchange Commission on November 12, 2026, seeking stockholder approval for an all-stock acquisition of Ferrox Critical Minerals Ltd. valued at $125 million.
Alaunos Therapeutics, Inc. filed a Form S-3 registration statement with the SEC on November 12, 2026, covering the proposed resale of up to 382,090,789 shares of common stock by selling stockholders connected to two transactions that closed in October 2026.